Evidence map›Paper›PMID 33932198›Full record

ArticleDigestive diseases and sciences2022

Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty.

Bharati D Kochar, Winston Cai, Ashwin N Ananthakrishnan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. A Comprehensive Review of Geriatric Syndromes and Assessment in Older Adults With Inflammatory Bowel Diseases.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence.JGH open : an open access journal of gastroenterology and hepatology · 2024
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Connecting the Dots: IBD and Frailty.Digestive diseases and sciences · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Bharati D KocharDivision of Gastroenterology, MGH Crohn's and Colitis Center, Massachusetts General Hospital, 165 Cambridge Street, 9th Floor, Boston, MA, 02114, USA.
Winston CaiDivision of Gastroenterology, MGH Crohn's and Colitis Center, Massachusetts General Hospital, 165 Cambridge Street, 9th Floor, Boston, MA, 02114, USA.
Ashwin N AnanthakrishnanDivision of Gastroenterology, MGH Crohn's and Colitis Center, Massachusetts General Hospital, 165 Cambridge Street, 9th Floor, Boston, MA, 02114, USA. aananthakrishnan@mgh.harvard.edu.ORCID 0000-0002-9436-1821
Massachusetts General Hospital · USHarvard University · US

Funding

Differential impact of smoking on the transcriptome and epigenome in Crohn's disease and ulcerative colitis"R21DK127227 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI ANANTHAKRISHNAN, ASHWIN N · 2020 to 2021
$369k
NIDDK NIH HHS R21 DK127227
6 · The paper itself

Abstract

backgroundFrailty may be a risk factor for complications in inflammatory bowel diseases (IBD) patients. We examined the impact of treatment on IBD patients who were frail prior to treatment and identified predictors of post-treatment change in frailty.

methodsIn an electronic health record-based cohort of IBD patients initiating anti-tumor necrosis factor (TNF)-α agents, we applied a validated claims-based frailty index to determine frailty in the 1 year prior to and after treatment initiation. We characterized treatment non-response using a composite outcome of IBD-related hospitalization, surgery, change in therapy, or initiation of systemic steroids. We constructed multivariable logistic regression models to identify determinants of post-treatment frailty.

resultsThe 1210 patients initiating anti-TNF therapy had a median age of 30 years; 20% were ≥ 50 years. In the first year after anti-TNF initiation, 40% were non-responders. Many more treatment non-responders were frail in the year following treatment compared with treatment responders (27% vs 7%, p < 0.001). Pre-treatment frailty (OR 2.01, 95% CI 1.35-3.00) and prior IBD-related hospitalization (OR 1.63, 95% CI 1.15-2.30) were independently predictive of higher likelihood of post-treatment frailty. Therapy response was associated with a lower likelihood (OR 0.24, 95% CI 0.16-0.34) of post-treatment frailty. Nearly 85% of patients who were frail prior to treatment demonstrated improvement in frailty following treatment

conclusionsResponse to anti-TNF therapy is an important determinant of post-treatment frailty in patients with IBD. Our findings suggest that effectively treating inflammatory states in older patients with IBD may improve frailty.

Indexed as

AdalimumabAdultColitis, UlcerativeCrohn DiseaseFemaleFrailtyHumansInflammatory Bowel DiseasesInfliximabLogistic ModelsMaleMiddle AgedMultivariate AnalysisTreatment OutcomeTumor Necrosis Factor InhibitorsYoung AdultAdalimumabInfliximabTumor Necrosis Factor InhibitorsAnti-tumor necrosis factorFrailtyFunctionInflammatory bowel diseaseTreatment

Identifiers

PMID33932198
PMCPMC8558109
OpenAlexW3158487177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.